John W. Eikelboom
YOU?
Author Swipe
View article: Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin
Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin Open
View article: Clinical impact of red cell storage duration: an individual patient data meta-analysis
Clinical impact of red cell storage duration: an individual patient data meta-analysis Open
View article: Bleeding in atrial fibrillation: unavoidable risk or modifiable target?
Bleeding in atrial fibrillation: unavoidable risk or modifiable target? Open
View article: Biomarker Analysis from the Compass Claudication Study – Rivaroxaban for Intermittent Claudication
Biomarker Analysis from the Compass Claudication Study – Rivaroxaban for Intermittent Claudication Open
Introduction A prospective, randomized, multicenter study compared rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily against aspirin 100 mg once daily alone in patients with peripheral artery disease and intermittent claudicati…
View article: The effects of low-dose colchicine on the progression of aortic valve stenosis: Rationale, design, and baseline characteristics of the Colchicine and Inflammation in Aortic Stenosis (CHIANTI) trial
The effects of low-dose colchicine on the progression of aortic valve stenosis: Rationale, design, and baseline characteristics of the Colchicine and Inflammation in Aortic Stenosis (CHIANTI) trial Open
Registered on ClinicalTrials.gov (https://clinicaltrials.gov/), ID: NCT05162742.
View article: Comparison of total event analysis and first event analysis in relation to heterogeneity in cardiovascular trials
Comparison of total event analysis and first event analysis in relation to heterogeneity in cardiovascular trials Open
View article: Reduced- compared with standard-dose direct oral anticoagulant in extended venous thromboembolism treatment: a systematic review and meta-analysis
Reduced- compared with standard-dose direct oral anticoagulant in extended venous thromboembolism treatment: a systematic review and meta-analysis Open
View article: Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial
Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial Open
Background The LoDoCo2 (Low‐Dose Colchicine 2) trial showed that colchicine reduced the risk for cardiovascular events in patients with chronic coronary syndrome. Current guidelines recommend colchicine use in selected high‐risk patients. …
View article: Risk factors associated with gastrointestinal bleeding in patients with cardiovascular disease (INTERBLEED): a case control study
Risk factors associated with gastrointestinal bleeding in patients with cardiovascular disease (INTERBLEED): a case control study Open
Aims This study aimed to identify and quantify the importance of risk factors for gastrointestinal (GI) bleeding in patients with CV disease. Methods and results We conducted a case-control study in 9 countries in Asia, America, Europe, an…
View article: Association of Biomarkers With Intracerebral Hematoma Expansion and Arterial Thromboembolic Events in Patients With Acute Intracranial Hemorrhage: The ANNEXA-I Biomarker Substudy
Association of Biomarkers With Intracerebral Hematoma Expansion and Arterial Thromboembolic Events in Patients With Acute Intracranial Hemorrhage: The ANNEXA-I Biomarker Substudy Open
BACKGROUND: ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors) was a randomized trial that demonstrated that andexanet compared with usual care in patients with intracranial hemorrhage associated w…
View article: Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort
Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort Open
In patients with CCS, Lp(a), OxPL-apo(a) and OxPL-apoB associated cardiovascular risk was only pertinent in those with elevated IL-6 but not hsCRP levels.
View article: Long COVID prevalence and risk factors in adults residing in middle- and high-income countries: secondary analysis of the multinational Anti-Coronavirus Therapies (ACT) trials
Long COVID prevalence and risk factors in adults residing in middle- and high-income countries: secondary analysis of the multinational Anti-Coronavirus Therapies (ACT) trials Open
Background During the recent COVID-19 pandemic, reports of long-term persistence or recurrence of symptoms after SARS-CoV-2 infection emerged, which are now collectively referred to as ‘long COVID’. Most descriptions of long COVID originat…
View article: Standard of care in advanced HIV disease: review of HIV treatment guidelines in sub-Saharan African countries—an extension study of eight countries
Standard of care in advanced HIV disease: review of HIV treatment guidelines in sub-Saharan African countries—an extension study of eight countries Open
Introduction The World Health Organization (WHO) has published guidelines for the management of patients with advanced HIV disease (AHD) but mortality remains high. Adoption of WHO recommendations by national guidelines is poorly documente…
View article: Sex Differences in Permanent Discontinuation of Trial Medication in Chronic Coronary Artery Disease: The LoDoCo2 Trial
Sex Differences in Permanent Discontinuation of Trial Medication in Chronic Coronary Artery Disease: The LoDoCo2 Trial Open
Contains fulltext : 317506.pdf (Publisher’s version ) (Open Access)
View article: Broadening the Healthy Aging Paradigm: Inclusion of Gestation, Development, and Reproductive Health
Broadening the Healthy Aging Paradigm: Inclusion of Gestation, Development, and Reproductive Health Open
The prevailing focus of lifespan health research has predominantly centered on “healthy aging”. This oversight may hinder the understanding of health across the lifespan, as disorders in earlier stages can substantially impact overall heal…
View article: Clinical significance of a new diagnosis of atrial fibrillation in patients with vascular disease
Clinical significance of a new diagnosis of atrial fibrillation in patients with vascular disease Open
In patients with vascular disease, a new diagnosis of AF was associated with a marked increase in risk of adverse outcomes, especially hospitalization for heart failure.
View article: Reduced Compared with Standard Dose Direct Oral Anticoagulant for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis
Reduced Compared with Standard Dose Direct Oral Anticoagulant for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis Open
View article: One-year outcomes of a single bolus r-SAK before primary PCI for STEMI: Follow-up of the OPTIMA-5 study
One-year outcomes of a single bolus r-SAK before primary PCI for STEMI: Follow-up of the OPTIMA-5 study Open
The OPTIMA-5 study demonstrated that a single bolus of half-dose recombinant staphylokinase (r-SAK) before primary percutaneous coronary intervention (PCI) significantly improved the patency of infarct related artery in patients with ST-el…
View article: Spirituality-Based Intervention in Hypertension: EFfects on Blood PrEssure and EndotheliaL Function—FEEL Trial Results
Spirituality-Based Intervention in Hypertension: EFfects on Blood PrEssure and EndotheliaL Function—FEEL Trial Results Open
A spirituality-based intervention was associated with improved control of office SBP and FMD. These findings will be prospectively evaluated in a nationwide larger and well-powered RCT.
View article: Usual On-therapy Ranges of Drug Concentrations in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants: A Systematic Review and Meta-analysis
Usual On-therapy Ranges of Drug Concentrations in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants: A Systematic Review and Meta-analysis Open
Although most patients with atrial fibrillation (AF) receiving a direct oral anticoagulant (DOAC) do not require drug concentration measurements, there are situations where such information could be useful. Existing guidance documents prov…
View article: Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation
Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation Open
Background Cardiac biomarkers improve risk prediction in patients with atrial fibrillation (AF). We recently demonstrated that the NFL (neuron‐specific protein neurofilament light chain) was associated with ischemic stroke in patients with…
View article: A sub-study of the POISE-3 randomized trial examined effects of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of acute kidney injury
A sub-study of the POISE-3 randomized trial examined effects of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of acute kidney injury Open
In this pre-specified sub-study of the POISE-3 trial, we examined the effect of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of postoperative acute kidney injury (AKI). Altogether, 730…
View article: Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the <scp>COMPASS</scp> Randomised Controlled Trial. Authors' Reply
Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the <span>COMPASS</span> Randomised Controlled Trial. Authors' Reply Open
View article: Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches
Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches Open
ORIGIN (NCT00069784). Registered on October 1, 2003; TRANSCEND (NCT00153101). Registered on September 9, 2005; COMPASS (NCT01776424). Registered on January 24, 2013; NAVIGATE-ESUS (NCT02313909). Registered on December 8, 2014.
View article: Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials
Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials Open
There was no funding source for this study.
View article: Exploration of the regional effects of colchicine in the LoDoCo2 trial
Exploration of the regional effects of colchicine in the LoDoCo2 trial Open
https://www.anzctr.org.au/ACTRN12614000093684.
View article: Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial
Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial Open
Aims This study aimed to compare the effects of the combination of rivaroxaban and aspirin with aspirin alone on health-related quality of life in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. Met…
View article: Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient‐Level Meta‐Analysis From COMBINE AF
Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient‐Level Meta‐Analysis From COMBINE AF Open
Background Despite oral anticoagulation, patients with atrial fibrillation (AF) remain at risk of ischemic stroke and systemic embolism (SE) events. For patients whose residual risk is sufficiently high, additional therapies might be usefu…
View article: Factor XI inhibition in cardiovascular disease
Factor XI inhibition in cardiovascular disease Open
Cardiovascular disease remains the leading global cause of mortality, requiring effective antithrombotic strategies to prevent thromboembolic events. Currently available therapies are effective but have inherent bleeding risks which may li…
View article: Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban, or the combination: Secondary analysis of the <scp>COMPASS</scp> randomised controlled trial
Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban, or the combination: Secondary analysis of the <span>COMPASS</span> randomised controlled trial Open
Summary Background The incidence of major gastrointestinal bleeding (GIB) in patients on low‐dose direct‐acting oral anticoagulants (DOACs) is relatively unknown. Estimates from randomised controlled trials (RCTs) are lacking. Aims To asse…